Xtant Medical Holdings Business Summary

Xtant Medical Holdings, Inc. (XTNT) is a vertically integrated medical technology firm specializing in the design, development, and commercialization of regenerative orthobiologics and spinal implant systems. The company generates revenue primarily through the sale of its comprehensive biologics portfolio—including the OsteoSponge, OsteoSelect DBM, and 3Demin product lines—and its spinal fixation hardware, which together target complex spine, deformity, and degenerative procedures. Following the December 2025 divestiture of its non-core Coflex and Paradigm Spine assets to Companion Spine for $19.2 million, Xtant has transitioned into a pure-play regenerative medicine company, leveraging its Belgrade, Montana, tissue processing facility to capture higher margins. It competes directly with major industry players such as Orthofix Medical, Atec Spine (Alphatec), Globus Medical, and SeaSpine, positioning itself as a specialized, operationally lean provider of advanced bone graft substitutes and surgical fixation solutions. The company’s leadership is led by President and CEO Sean Browne, a medical device veteran with over 30 years of experience who previously held senior roles at Integra LifeSciences, McKesson, and Baxter Healthcare. He is supported by CFO Scott Neils, a CPA with a background in audit management at Baker Tilly and Grant Thornton, and COO Mark Schallenberger, who brings over 12 years of orthobiologics expertise from Surgenex and DCI Donor Services. Xtant was formed through the 2015 merger of Bacterin International, founded by Guy Cook in 1998, and X-spine Systems, founded by Dr. David Kirschman in 2003. The company is backed by notable institutional investors, most significantly Nantahala Capital Management, which holds a nearly 50% stake, alongside AWM Investment Company and Vanguard. The Board of Directors is chaired by Jeffrey Peters, a seasoned healthcare executive and former Managing Director at Geisinger Ventures.